Target intelligence / Profile preview

Alanine racemase and D-alanine–D-alanine ligase (Alr (for alanine racemase), Ddl (for D-alanine–D-alanine ligase))

Target
Alr (for alanine racemase), Ddl (for D-alanine–D-alanine ligase)
Molecular classification
Enzyme; Isomerase (specifically, a racemase/epimerase acting on amino acids), Enzyme (Ligase/ATP grasp enzyme superfamily)
01

Overview

Alanine racemase is a pyridoxal phosphate (PLP)-dependent enzyme that catalyzes the reversible racemization of L-alanine to D-alanine, a step essential for peptidoglycan biosynthesis in bacteria. D-alanine–D-alanine ligase catalyzes the ATP-dependent ligation of two D-alanine molecules to form the dipeptide D-Ala–D-Ala, which is then incorporated into the bacterial cell wall peptide chain. Both enzymes are absent in higher eukaryotes and are essential for bacterial viability, making them prime targets for antibiotic development, particularly D-cycloserine, which inhibits both. Their inhibition leads to disruption of cell wall synthesis and bacterial lysis.

Other names
L-alanine racemaseAlrEC 5.1.1.1DdlEC 6.3.2.4
02

Mechanism of action

Inhibition of alanine racemase blocks racemization of L-alanine to D-alanine, depleting D-alanine needed for cell wall synthesis. Inhibition of D-alanine–D-alanine ligase blocks dipeptide formation essential for peptidoglycan crosslinking. D-cycloserine acts by irreversible covalent modification (alanine racemase), and through phosphorylation-based inhibition (D-alanine–D-alanine ligase).

03

Biological functions

Racemization of L-alanine to D-alanine, providing D-alanine for essential processesATP-dependent ligation of two D-alanine molecules to form D-Ala–D-Ala dipeptideProvide D-alanine and D-Ala–D-Ala dipeptide, both essential precursors for bacterial peptidoglycan (cell wall) biosynthesis
04

Disease associations

Infection (essential for bacterial survival; absent in mammals, making them selective antibacterial targets)Other (resistance, especially in tuberculosis and other Gram-positive/negative pathogens)
05

Safety considerations

Neurotoxicity (notably for D-cycloserine)Resistance (mutations/overproduction of targets in pathogens such as Mycobacterium tuberculosis)Off-target effects due to similarity with other PLP-dependent enzymes in microbes
06

Interacting drugs

D-cycloserine (inhibits both alanine racemase and D-alanine–D-alanine ligase)

2 more in the full profile.

07

Biomarkers

No established clinical biomarkers for patient selection.Essentiality in bacterial genomes can be used as a surrogate in research.

Beyond the preview

Go deeper on Alanine racemase and D-alanine–D-alanine ligase (Alr (for alanine racemase), Ddl (for D-alanine–D-alanine ligase)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alanine racemase and D-alanine–D-alanine ligase (Alr (for alanine racemase), Ddl (for D-alanine–D-alanine ligase)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call